Ticker
AFMD

Price
1.20
Stock movement down
-0.08 (-6.25%)
Company name
Affimed NV
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
179.21M
Ent value
11.61M
Price/Sales
4.42
Price/Book
0.99
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-69.70%
3 year return
-23.59%
5 year return
-8.29%
10 year return
-
Last updated: 2023-02-03

DIVIDENDS

AFMD does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.42
Price to Book0.99
EV to Sales0.29

FINANCIALS

Per share

Loading...
Per share data
Current share count149.34M
EPS (TTM)-0.51
FCF per share (TTM)-0.70

Income statement

Loading...
Income statement data
Revenue (TTM)40.53M
Gross profit (TTM)0.00
Operating income (TTM)-82.18M
Net income (TTM)-75.65M
EPS (TTM)-0.51
EPS (1y forward)-0.81

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-202.75%
Profit margin (TTM)-186.64%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash222.90M
Net receivables1.69M
Total current assets230.55M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets236.40M
Accounts payable15.08M
Short/Current long term debt18.73M
Total current liabilities40.83M
Total liabilities55.30M
Shareholder's equity181.10M
Net tangible assets179.55M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-101.57M
Capital expenditures (TTM)2.61M
Free cash flow (TTM)-104.18M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-41.77%
Return on Assets-32.00%
Return on Invested Capital-37.90%
Cash Return on Invested Capital-52.19%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.28
Daily high1.28
Daily low1.19
Daily Volume1.30M
All-time high21.93
1y analyst estimate7.68
Beta2.37
EPS (TTM)-0.51
Dividend per share-
Ex-div date-
Next earnings date29 Mar 2023

Downside potential

Loading...
Downside potential data
AFMDS&P500
Current price drop from All-time high-94.53%-13.68%
Highest price drop-95.19%-56.47%
Date of highest drop10 Jan 20239 Mar 2009
Avg drop from high-75.95%-11.49%
Avg time to new high85 days13 days
Max time to new high1902 days1805 days
COMPANY DETAILS
AFMD (Affimed NV) company logo
Marketcap
179.21M
Marketcap category
Small-cap
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; Roivant Sciences Ltd.; and Artiva Biotherapeutics Inc., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Employees
197
Investor relations
-
SEC filings
CEO
Adolf Hoess
Country
USA
City
Heidelberg
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
AFM13 combination with Artiva’s AB-101 NK cells: Received written feedback to pre-investigational new drug (IND) meeting request which supports plan for IND filing in H1 2023 and initiation of clinica...
January 9, 2023
Even the best investor on earth makes unsuccessful investments. But it's not unreasonable to try to avoid truly...
December 28, 2022
AFM28 monotherapy receives authorization of a Clinical Trial Application (CTA) for the phase 1 study by the French National Agency for the Safety of Medicines and Health Products (ANSM)Initiation of A...
December 22, 2022
Affimed N.V. (AFMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revis...
December 16, 2022
H.C. Wainwright initiated coverage on Affimed NV (NASDAQ: AFMD), a clinical-stage biotechnology company focused on developing innate cell engagers (ICEs) for cancer treatment. The analyst has a Buy ra...
December 12, 2022
AFM28 efficiently directs allogeneic NK cells to CD123-positive leukemic cells, including leukemic stem and progenitor cells, inducing their depletion in samples of patients with Acute Myeloid Leukemi...
December 12, 2022
Affimed N.V. (NASDAQ: AFMD) announced topline data from its phase 2 REDIRECT study of AFM13 monotherapy in patients with advanced-stage relapsed/refractory peripheral T cell lymphoma (r/r PTCL). Prima...
December 12, 2022
Data from REDIRECT establish that AFM13 monotherapy is effective in the treatment of relapsed/refractory peripheral T cell lymphoma (r/r PTCL) patients with a differentiated safety profile AFM13 demon...
December 10, 2022
AFM13 in combination with NK cells shows very high overall and complete response rates in 41 heavily pre-treated CD30-positive Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL) patientsPatients had...
December 10, 2022
Review of clinical data and development plans for AFM13 in hematologic malignanciesLive event and webcast on Saturday, December 10 at 4:00 p.m. CST HEIDELBERG, Germany,, Dec. 01, 2022 (GLOBE NEWSWIRE)...
December 1, 2022
Next page